Viral Vaccine Vectors to Prevent Hepatocellular Carcinoma
预防肝细胞癌的病毒疫苗载体
基本信息
- 批准号:8092019
- 负责人:
- 金额:$ 4.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-01 至 2012-04-30
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAnimalsAntibody FormationApoptosisAttenuatedAvidityCD8B1 geneCessation of lifeChronic HepatitisChronic Hepatitis BCore ProteinDataDiseaseDoseGlycoproteinsHepatitis BHepatitis B VaccinesHepatitis B VirusHepatocyteHistologyImmune responseImmunityImmunizationIndividualInfectionInfection preventionInflammationInterleukin-2LeadLigandsLiverLiver CirrhosisMalignant neoplasm of liverMeasuresMemoryModelingMusPlasmidsPrimary carcinoma of the liver cellsProductionRecombinantsSerumSimian B diseaseSouthern BlottingSpecificitySpleenStaining methodStainsStructural ProteinSurfaceT cell responseT-LymphocyteTestingTherapeuticTimeTransfectionTransgenic MiceVaccinatedVaccinationVaccinesVaccinia virusVesicular stomatitis Indiana virusViral ProteinsViral VaccinesVirusVirus Replicationcytokineenzyme linked immunospot assayimmunogenicityimprovedkillingsmouse modelneutralizing antibodynovel strategiespathogenpreventprophylacticpublic health relevanceresponsetherapeutic vaccinevectorvector vaccinevector-inducedviral resistancevirus core
项目摘要
DESCRIPTION (provided by applicant): Infection with the hepatitis B virus (HBV) can lead to chronic hepatitis and hepatocellular carcinoma. Current therapies for chronic HBV infection are only moderately effective, and are limited by severe side effects and viral resistance. Thus, there remains a need for new therapies for this serious disease. The host T cell response to HBV is vigorous and multi-specific in acutely infected people who clear the virus, but it is weak and narrowly focused in those who become chronically infected. Therapeutic vaccination to induce an immune response sufficient to control the virus is a possible new approach for the treatment of chronic hepatitis B. Unfortunately; the current HBV vaccine is not effective for therapeutic vaccination. Although it produces a strong neutralizing antibody response that prevents infection, it does not induce the potent CD8 T cell response needed to eliminate the virus after infection. The current vaccine is also not optimal for widespread prophylactic vaccination in endemic underdeveloped regions of the world, as it does not induce protection in all individuals, the protective antibody response decreases over time, and multiple doses are required for long-lasting immunity. Recombinant vesicular stomatitis virus (VSV) vaccine vectors induce strong protective CD8 T cell and antibody responses to a variety of pathogens, and are also showing promise as therapeutic vaccines. We will test the hypothesis that recombinant VSV expressing the HBV structural proteins will make effective vaccines for prophylactic and therapeutic immunization against HBV. We will generate recombinant VSV vaccine vectors that express HBV proteins, characterize the immune response to VSV/HBV in vaccinated animals, and determine if VSV/HBV vaccine vectors induce an effective immune response in mouse models of chronic HBV. An improved prophylactic vaccine that provides long-term immunity in a single dose or an effective therapeutic vaccine would have the potential to prevent millions of cases of HBV-associated hepatocellular carcinoma.
Public Health Relevance: Chronic hepatitis B virus (HBV) infection leads to millions of deaths each year worldwide from liver cirrhosis and hepatocellular carcinoma. Current therapies for HBV infection are only moderately effective, and are often accompanied by severe side effects and viral resistance. An improved prophylactic vaccine and/or an effective therapeutic vaccine would have the potential to prevent millions of cases of HBV-associated liver cancer.
描述(由申请人提供):丙型肝炎病毒(HBV)感染可导致慢性肝炎和肝细胞癌。慢性HBV感染的当前疗法仅适度有效,并且受到严重的副作用和病毒抗性的限制。因此,仍然需要解决这种严重疾病的新疗法。在清除病毒的急性感染者中,宿主T细胞对HBV的反应是剧烈且多特异性的,但它弱且狭窄地集中在被长期感染的人中。治疗性疫苗接种以诱导足以控制病毒的免疫反应是治疗慢性乙型肝炎的一种新方法。不幸的是。当前的HBV疫苗对治疗疫苗无效。尽管它产生了防止感染的强中和抗体反应,但它不会诱导感染后消除病毒所需的有效的CD8 T细胞反应。当前的疫苗也不是世界各地欠发达地区广泛预防性疫苗接种的最佳选择,因为它并不引起所有个体的保护,随着时间的推移,保护性抗体反应会降低,并且需要多种剂量才能进行长期免疫力。重组囊泡口腔炎病毒(VSV)疫苗载体诱导强烈的保护性CD8 T细胞和对多种病原体的抗体反应,并且也表现为治疗性疫苗的希望。我们将测试以下假设:表达HBV结构蛋白的重组VSV将对针对HBV进行预防性和治疗性免疫有效疫苗。我们将生成表达HBV蛋白的重组VSV疫苗向量,表征对接种疫苗的动物对VSV/HBV的免疫反应,并确定VSV/HBV疫苗载体是否在慢性HBV小鼠模型中诱导有效的免疫反应。改进的预防性疫苗可在单剂量或有效的治疗疫苗中提供长期免疫力,将有可能预防数百万例HBV相关的肝细胞癌。
公共卫生相关性:慢性肝炎病毒(HBV)感染每年因肝肝硬化和肝细胞癌而导致全世界数百万死亡。 HBV感染的当前疗法仅适度有效,并且通常伴有严重的副作用和病毒抗性。改善的预防性疫苗和/或有效的治疗疫苗有可能预防数百万例HBV相关的肝癌。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL ROBEK其他文献
MICHAEL ROBEK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL ROBEK', 18)}}的其他基金
Human mechanisms of virus persistence in an AAV-based mouse model of chronic HBV infection
基于 AAV 的慢性 HBV 感染小鼠模型中病毒持续存在的人类机制
- 批准号:
10057461 - 财政年份:2020
- 资助金额:
$ 4.74万 - 项目类别:
Human mechanisms of virus persistence in an AAV-based mouse model of chronic HBV infection
基于 AAV 的慢性 HBV 感染小鼠模型中病毒持续存在的人类机制
- 批准号:
10391508 - 财政年份:2020
- 资助金额:
$ 4.74万 - 项目类别:
Human mechanisms of virus persistence in an AAV-based mouse model of chronic HBV infection
基于 AAV 的慢性 HBV 感染小鼠模型中病毒持续存在的人类机制
- 批准号:
10614465 - 财政年份:2020
- 资助金额:
$ 4.74万 - 项目类别:
Human mechanisms of virus persistence in an AAV-based mouse model of chronic HBV infection
基于 AAV 的慢性 HBV 感染小鼠模型中病毒持续存在的人类机制
- 批准号:
10159211 - 财政年份:2020
- 资助金额:
$ 4.74万 - 项目类别:
A new humanized mouse model of chronic hepatitis B
一种新的慢性乙型肝炎人源化小鼠模型
- 批准号:
8707714 - 财政年份:2014
- 资助金额:
$ 4.74万 - 项目类别:
Enhancing Oncolytic Virotherapy with Type III Interferon
使用 III 型干扰素增强溶瘤病毒治疗
- 批准号:
8638209 - 财政年份:2013
- 资助金额:
$ 4.74万 - 项目类别:
ENHANCING ONCOLYTIC VIROTHERAPY WITH TYPE III INTERFERON
使用 III 型干扰素增强溶瘤病毒治疗
- 批准号:
8989222 - 财政年份:2013
- 资助金额:
$ 4.74万 - 项目类别:
2011 International Meeting on the Molecular Biology of Hepatitis B Viruses
2011年乙型肝炎病毒分子生物学国际会议
- 批准号:
8122011 - 财政年份:2011
- 资助金额:
$ 4.74万 - 项目类别:
Viral Vaccine Vectors to Prevent Hepatocellular Carcinoma
预防肝细胞癌的病毒疫苗载体
- 批准号:
7848367 - 财政年份:2008
- 资助金额:
$ 4.74万 - 项目类别:
Viral Vaccine Vectors to Prevent Hepatocellular Carcinoma
预防肝细胞癌的病毒疫苗载体
- 批准号:
7900191 - 财政年份:2008
- 资助金额:
$ 4.74万 - 项目类别:
相似国自然基金
基于扁颅蝠类群系统解析哺乳动物脑容量适应性减小的演化机制
- 批准号:32330014
- 批准年份:2023
- 资助金额:215 万元
- 项目类别:重点项目
基于供应链视角的动物源性食品中抗微生物药物耐药性传导机制及监管策略研究
- 批准号:72303209
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于基因组数据自动化分析为后生动物类群大规模开发扩增子捕获探针的实现
- 批准号:32370477
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
大型野生动物对秦岭山地森林林下植物物种组成和多样性的影响及作用机制
- 批准号:32371605
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
闸坝建设对河口大型底栖动物功能与栖息地演变的影响-以粤西鉴江口为例
- 批准号:42306159
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Selective actin remodeling of sensory neurons for acute pain management
感觉神经元的选择性肌动蛋白重塑用于急性疼痛管理
- 批准号:
10603436 - 财政年份:2023
- 资助金额:
$ 4.74万 - 项目类别:
Targeting ferroptosis in renal tubular epithelial cells to improve outcomes of lupus nephritis
靶向肾小管上皮细胞铁死亡以改善狼疮性肾炎的预后
- 批准号:
10638468 - 财政年份:2023
- 资助金额:
$ 4.74万 - 项目类别:
(Attack)2: Genetic engineering of cellular and humoral immunity to cure HIV
(攻击)2:细胞和体液免疫基因工程治愈艾滋病毒
- 批准号:
10468647 - 财政年份:2020
- 资助金额:
$ 4.74万 - 项目类别:
(Attack)2: Genetic engineering of cellular and humoral immunity to cure HIV
(攻击)2:细胞和体液免疫基因工程治愈艾滋病毒
- 批准号:
10160814 - 财政年份:2020
- 资助金额:
$ 4.74万 - 项目类别:
(Attack)2: Genetic engineering of cellular and humoral immunity to cure HIV
(攻击)2:细胞和体液免疫基因工程治愈艾滋病毒
- 批准号:
9890819 - 财政年份:2020
- 资助金额:
$ 4.74万 - 项目类别: